留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x

粪菌移植在炎症性肠病中的应用进展

陈嘉楠 吴思丽 邱欣帆 李志锋 程淇 毛华

陈嘉楠, 吴思丽, 邱欣帆, 李志锋, 程淇, 毛华. 粪菌移植在炎症性肠病中的应用进展[J]. 分子影像学杂志, 2019, 42(3): 353-357. doi: 10.12122/j.issn.1674-4500.2019.03.18
引用本文: 陈嘉楠, 吴思丽, 邱欣帆, 李志锋, 程淇, 毛华. 粪菌移植在炎症性肠病中的应用进展[J]. 分子影像学杂志, 2019, 42(3): 353-357. doi: 10.12122/j.issn.1674-4500.2019.03.18
Jianan CHEN, Sili WU, Xinfan QIU, Zhifeng LI, Qi CHENG, Hua MAO. Therapeutic application of fecal microbiota transplantation in inflammatory bowel disease[J]. Journal of Molecular Imaging, 2019, 42(3): 353-357. doi: 10.12122/j.issn.1674-4500.2019.03.18
Citation: Jianan CHEN, Sili WU, Xinfan QIU, Zhifeng LI, Qi CHENG, Hua MAO. Therapeutic application of fecal microbiota transplantation in inflammatory bowel disease[J]. Journal of Molecular Imaging, 2019, 42(3): 353-357. doi: 10.12122/j.issn.1674-4500.2019.03.18

粪菌移植在炎症性肠病中的应用进展

doi: 10.12122/j.issn.1674-4500.2019.03.18
基金项目: 南方医科大学大学生创新训练项目省级课题(201812121178)
详细信息
    作者简介:

    陈嘉楠,本科,E-mail:1241857377@qq.com

    通讯作者:

    毛 华,博士,主任医师,E-mail:maohua1963@126.com

Therapeutic application of fecal microbiota transplantation in inflammatory bowel disease

  • 摘要: 炎症性肠病是一组慢性非特异性肠道炎症性疾病,包括溃疡性结肠炎和克罗恩病,其发病原因尚不明确,研究表明肠道菌群紊乱在炎症性肠病的发病中起重要作用,而粪菌移植作为一种可以重建肠道菌群的疗法,在炎症性肠病的临床应用上有重要价值。粪菌移植是将健康个体的粪便处理成混悬液,输注到炎症性肠病患者消化道内,重建肠道微生态,从而有效缓解炎症性肠病病情。但目前粪菌移植在炎症性肠病上的临床应用仍存在不少问题,如供体的筛选、粪菌液的制备、移植的途径及频次等方面均未形成共识。本文就粪菌移植的在炎症性肠病中的应用进展进行综述。

     

  • [1] 吴开春, 梁 洁, 冉志华, 等. 炎症性肠病诊断与治疗的共识意见(2018年·北京)[J]. 中国实用内科杂志, 2018, 32(9): 796-813.
    [2] 王玉芳, 欧阳钦, 胡仁伟, 等. 炎症性肠病流行病学研究进展[J]. 胃肠病学, 2013, 18(1): 48-51. doi: 10.3969/j.issn.1008-7125.2013.01.012
    [3] Regner EH, Ohri N, Stahly A, et al. Functional intraepithelial lymphocyte changes in inflammatory bowel disease and spondyloarthritis have disease specific correlations with intestinal microbiota[J]. Arthritis Res Ther, 2018, 20(1): 149-61. doi: 10.1186/s13075-018-1639-3
    [4] Manichanh C, Borruel N, Casellas FA. The gut microbiota in IBD[J]. Nat Rev Gastroenterol Hepatol, 2012, 9(10): 599-608. doi: 10.1038/nrgastro.2012.152
    [5] Sartor RB, Mazmanian SK. Intestinal microbes in inflammatory bowel diseases[J]. Am J Gastroenterol Suppl, 2012, 1(1): 15-21. doi: 10.1038/ajgsup.2012.4
    [6] 孙铭晟, 逯茂洋. 肠道菌群与炎症性肠病研究进展[J]. 世界最新医学信息文摘, 2017, 23(102): 48-9.
    [7] Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of clostridium difficile infections[J]. Am J Gastroenterol, 2013, 108(4): 478-99. doi: 10.1038/ajg.2013.4
    [8] Halkjaer SI, Christensen AH, Lo BZ, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study[J]. Gut, 2018, 67(12): 2107-15. doi: 10.1136/gutjnl-2018-316434
    [9] Bajaj JS, Kassam Z, Fagan A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial[J]. Hepatology, 2017, 66(6): 1727-38. doi: 10.1002/hep.29306
    [10] Cammarota G, Ianiro G, Tilg HA, et al. European consensus conference on faecal microbiota transplantation in clinical practice[J]. Gut, 2017, 66(4): 569-80. doi: 10.1136/gutjnl-2016-313017
    [11] Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis[J]. Gastroenterology, 2015, 149(1): 110-8. doi: 10.1053/j.gastro.2015.03.045
    [12] Fang H, Fu L, Wang J. Protocol for fecal microbiota transplantation in inflammatory bowel disease: a systematic review and meta-analysis[J]. Biomed Res Int, 2018, 20(1): 1-11.
    [13] 向 杰, 张发明, 黄光明. 粪菌移植的方法学及其治疗炎症性肠病的研究进展[J]. 胃肠病学, 2016, 21(2): 121-4. doi: 10.3969/j.issn.1008-7125.2016.02.015
    [14] 张发明. 粪菌移植体系[J]. 科技导报, 2016, 34(20): 86-92.
    [15] Smits LP, Bouter KE, de Vos WM, et al. Therapeutic potential of fecal microbiota transplantation[J]. Gastroenterology, 2013, 145(5): 946-53. doi: 10.1053/j.gastro.2013.08.058
    [16] Hamilton MJ, Weingarden AR, Sadowsky MJ, et al. Standardized frozen preparation for transplantation of fecal microbiota for recurrent clostridium difficile infection[J]. Am J Gastroenterol, 2012, 107(5): 761-7. doi: 10.1038/ajg.2011.482
    [17] Costello SP, Conlon MA, Vuaran MS, et al. Faecal microbiota transplant for recurrent clostridium difficile infection using long-term frozen stool is effective: clinical efficacy and bacterial viability data[J]. Aliment Pharmacol Ther, 2015, 42(8): 1011-8. doi: 10.1111/apt.13366
    [18] Kunde S, Pham A, Bonczyk S, et al. Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis[J]. J Pediatr Gastroenterol Nutr, 2013, 56(6): 597-601. doi: 10.1097/MPG.0b013e318292fa0d
    [19] Peng Z, Xiang J, He Z, et al. Colonic transendoscopic enteral tubing: A novel way of transplanting fecal microbiota[J]. Endosc Int Open, 2016, 4(6): E610-3. doi: 10.1055/s-00025476
    [20] Kellermayer R, Nagy-Szakal D, Harris R, et al. Serial fecal microbiota transplantation alters mucosal gene expression in pediatric ulcerative colitis[J]. Am J Gastroenterol, 2015, 110(4): 604-6. doi: 10.1038/ajg.2015.19
    [21] Angelberger S, Reinisch W, Makristathis A, et al. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation[J]. Am J Gastroenterol, 2013, 108(10): 1620-30. doi: 10.1038/ajg.2013.257
    [22] Bennet JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora[J]. Lancet, 1989, 1(8630): 164-75.
    [23] Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial[J]. Gastroenterology, 2015, 149(1): 102-9. doi: 10.1053/j.gastro.2015.04.001
    [24] Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial[J]. Lancet, 2017, 389(175): 1218-28.
    [25] Costello S, Waters O, Bryant R, et al. OP036 short duration, low intensity pooled faecal microbiota transplantation induces remission in patients with mild-moderately active ulcerative colitis: a randomised controlled trial[J]. J Crohns Colitis, 2017, 11(suppl): S23-35.
    [26] Borody TJ, George L, Andrews P, et al. Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome[J]. Med J Aust, 1989, 150(10): 604-17.
    [27] Suskind DL, Brittnacher MJ, Wahbeh G, et al. Fecal microbial transplant effect on clinical outcomes and fecal microbiome in active Crohn's disease[J]. Inflamm Bowel Dis, 2015, 21(3): 556-63. doi: 10.1097/MIB.0000000000000307
    [28] Cui B, Feng Q, Wang H, et al. Fecal microbiota transplantation through mid-gut for refractory Crohn's disease: safety, feasibility, and efficacy trial results[J]. J Gastroenterol Hepatol, 2015, 30(1): 51-8. doi: 10.1111/jgh.12727
    [29] Vaughn BP, Vatanen T, Allegretti JR, et al. Increased intestinal microbial diversity following fecal microbiota transplant for active crohn's disease[J]. Inflamm Bowel Dis, 2016, 22(9): 2182-90. doi: 10.1097/MIB.0000000000000893
    [30] Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis[J]. J Crohns Colitis, 2014, 8(12): 1569-81. doi: 10.1016/j.crohns.2014.08.006
    [31] Wang S, Xu MQ, Wang WQ, et al. Systematic review: adverse events of fecal microbiota transplantation[J]. PLoS One, 2016, 11(8): e161174-85.
    [32] Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of the literature[J]. J Hosp Infect, 2016, 92(2): 117-27. doi: 10.1016/j.jhin.2015.10.024
    [33] Kelly BJ, Tebas P. Clinical practice and infrastructure review of fecal microbiota transplantation for clostridium difficile infection[J]. Chest, 2018, 153(1): 266-77. doi: 10.1016/j.chest.2017.09.002
    [34] Wang HG, Cui BT, Li Q, et al. The safety of fecal microbiota transplantation for crohn's disease: findings from a Long-Term study[J]. Adv Ther, 2018, 35(11): 1935-44. doi: 10.1007/s12325-018-0800-3
    [35] Hsu WH, Wang JY, Kuo CH. Current applications of fecal microbiota transplantation in intestinal disorders[J]. Kaohsiung J Med Sci, 2019, 35(6): 327-31.
    [36] Vermeire S, Joossens M, Verbeke K, et al. Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease[J]. J Crohns Colitis, 2016, 10(4): 387-94. doi: 10.1093/ecco-jcc/jjv203
    [37] Wilson BC, Vatanen T, Cutfield WS. The super-donor phenomenon in fecal microbiota transplantation[J]. Front Cell Infect Microbiol, 2019, 9(2): 135-45.
    [38] Hohmann EL, Ananthakrishnan AN, Deshpande V. Case records of the Massachusetts general hospital case 25-2014, a 37-year-old man with ulcerative colitis and bloody diarrhea[J]. N Engl J Med, 2014, 371(7): 668-75. doi: 10.1056/NEJMcpc1400842
    [39] Hocquart M, Lagier JC, Cassir NA, et al. Early fecal microbiota transplantation improves survival in severe clostridium difficile infections[J]. Clinical Infectious Diseases, 2018, 66(5): 645-50. doi: 10.1093/cid/cix762
    [40] Bakken JS, Borody T, Brandt LJ, et al. Treating clostridium difficile infection with fecal microbiota transplantation[J]. Clin Gastroenterol Hepatol, 2011, 9(12): 1044-9. doi: 10.1016/j.cgh.2011.08.014
  • 加载中
计量
  • 文章访问数:  1610
  • HTML全文浏览量:  588
  • PDF下载量:  13
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-05-12
  • 刊出日期:  2019-07-01

目录

    /

    返回文章
    返回

    关于《分子影像学杂志》变更刊期通知

    各位专家、作者、读者:

    为了缩短出版时滞,促进科研成果的快速传播,我刊自2024年1月起,刊期由双月刊变更为月刊。本刊主要栏目有:基础研究、临床研究、技术方法、综述等。

    感谢各位专家、作者、读者长期以来对我刊的支持与厚爱!

    南方医科大学学报编辑部

    《分子影像学杂志》

    2023年12月27日